ENTRY       D11943                      Drug
NAME        Molnupiravir (JAN/USAN);
            Lagevrio (TN)
PRODUCT
  OTHER     LAGEVRIO (Merck Sharp & Dohme LLC)
FORMULA     C13H19N3O7
EXACT_MASS  329.1223
MOL_WEIGHT  329.3059
CLASS       Antiviral
             DG03174  Anti-SARS-CoV-2 agent
REMARK      Therapeutic category: 6250
            ATC code: J05AB18
            Product: D11943<JP/US>
EFFICACY    Antiviral, RNA polymerase inhibitor
  DISEASE   Coronavirus disease 2019 [DS:H02398]
COMMENT     Ribonucleoside analogue
            Treatment of infections caused by RNA viral pathogens, including SARS-CoV-2
TARGET      SARS coronavirus replicase [KO:K24149]
  PATHWAY   ko03230(K24149)  Viral genome structure
            ko05171(K24149)  Coronavirus disease - COVID-19
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             J ANTIINFECTIVES FOR SYSTEMIC USE
              J05 ANTIVIRALS FOR SYSTEMIC USE
               J05A DIRECT ACTING ANTIVIRALS
                J05AB Nucleosides and nucleotides excl. reverse transcriptase inhibitors
                 J05AB18 Molnupiravir
                  D11943  Molnupiravir (JAN/USAN) &lt;JP/US&gt;
            Therapeutic category of drugs in Japan [BR:br08301]
             6  Agents against pathologic organisms and parasites
              62  Chemotherapeutics
               625  Antivirals
                6250  Antivirals
                 D11943  Molnupiravir (JAN/USAN)
            Drug groups [BR:br08330]
             Antiviral
              DG03174  Anti-SARS-CoV-2 agent
               D11943  Molnupiravir
            Drug classes [BR:br08332]
             Antiviral
              DG03174  Anti-SARS-CoV-2 agent
               D11943  Molnupiravir
            Antimicrobials [BR:br08307]
             Antivirals
              Genome replication inhibitor
               Other inhibitor
                D11943  Molnupiravir (JAN/USAN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D11943
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D11943
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11943
DBLINKS     CAS: 2492423-29-5
            ChEBI: 180653
ATOM        23
            1   C8x C    17.8926  -17.2912
            2   N4y N    17.8926  -18.6989
            3   C8y C    19.0892  -19.4028
            4   N4x N    20.3562  -18.6989
            5   C8y C    20.3562  -17.2912
            6   C8x C    19.0892  -16.5873
            7   C1y C    16.6960  -19.4028
            8   O2x O    15.4995  -18.6286
            9   C1y C    14.4437  -19.4732
            10  C1y C    14.8660  -20.7402
            11  C1y C    16.2737  -20.7402
            12  C1b C    13.2471  -18.7693
            13  O7a O    12.0505  -19.4732
            14  C7a C    10.8539  -18.7693
            15  C1c C     9.6573  -19.4732
            16  C1a C     8.4608  -18.7693
            17  C1a C     9.6573  -20.8809
            18  O6a O    10.8539  -17.3616
            19  N2b N    21.5527  -16.5873
            20  O1b O    22.8197  -17.2912
            21  O1a O    14.0213  -21.8664
            22  O1a O    17.1184  -21.8664
            23  O5x O    19.1423  -20.7895
BOND        24
            1     1   2 1
            2     2   3 1
            3     3   4 1
            4     4   5 1
            5     5   6 1
            6     1   6 2
            7     7   2 1 #Up
            8     7   8 1
            9     8   9 1
            10    9  10 1
            11   10  11 1
            12    7  11 1
            13    9  12 1 #Up
            14   12  13 1
            15   13  14 1
            16   14  15 1
            17   15  16 1
            18   15  17 1
            19   14  18 2
            20    5  19 2
            21   19  20 1
            22   10  21 1 #Down
            23   11  22 1 #Down
            24    3  23 2
///
